Show simple item record

dc.contributor.authorMcConnell, Michael J 
dc.contributor.authorMartin-Galiano, Antonio Javier 
dc.date.accessioned2021-05-12T09:14:22Z
dc.date.available2021-05-12T09:14:22Z
dc.date.issued2021
dc.identifier.citationFront Immunol. 2021 Apr 16;12:666742.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/12937
dc.description.abstractVaccines and monoclonal antibodies are promising approaches for preventing and treating infections caused by multidrug resistant Acinetobacter baumannii. However, only partial protection has been achieved with many previously tested protein antigens, which suggests that vaccines incorporating multiple antigens may be necessary in order to obtain high levels of protection. Several aspects that use the wealth of omic data available for A. baumannii have not been fully exploited for antigen identification. In this study, the use of fractionated proteomic and computational data from ~4,200 genomes increased the number of proteins potentially accessible to the humoral response to 8,824 non-redundant proteins in the A. baumannii panproteome. Among them, 59% carried predicted B-cell epitopes and T-cell epitopes recognized by two or more alleles of the HLA class II DP supertype. Potential cross-reactivity with human proteins was detected for 8.9% of antigens at the protein level and 2.7% at the B-cell epitope level. Individual antigens were associated with different infection types by genomic, transcriptomic or functional analyses. High intra-clonal genome density permitted the identification of international clone II as a "vaccitype", in which 20% of identified antigens were specific to this clone. Network-based centrality measurements were used to identify multiple immunologic nodes. Data were formatted, unified and stored in a data warehouse database, which was subsequently used to identify synergistic antigen combinations for different vaccination strategies. This study supports the idea that integration of multi-omic data and fundamental knowledge of the pathobiology of drug-resistant bacteria can facilitate the development of effective multi-antigen vaccines against these challenging infections.es_ES
dc.description.sponsorshipThis research was supported by Acción Estratégica en Salud from the ISCIII, grants MPY 380/18 and MPY 509/19. AM-G is the recipient of a Miguel Servet contract by the ISCIII.es_ES
dc.language.isoenges_ES
dc.publisherFrontiers Mediaes_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectantibiotic resistancees_ES
dc.subjectepitopees_ES
dc.subjectmultidrug resistancees_ES
dc.subjectreverse vaccinologyes_ES
dc.subjectsystems biologyes_ES
dc.titleDesigning Multi-Antigen Vaccines Against Acinetobacter baumannii Using Systemic Approaches.es_ES
dc.typeArtículoes_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID33936107es_ES
dc.format.volume12es_ES
dc.format.page666742es_ES
dc.identifier.doi10.3389/fimmu.2021.666742es_ES
dc.contributor.funderInstituto de Salud Carlos III
dc.description.peerreviewedes_ES
dc.identifier.e-issn1664-3224es_ES
dc.relation.publisherversionhttps://doi.org/10.3389/fimmu.2021.666742es_ES
dc.identifier.journalFrontiers in Immunologyes_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/MPY 380/18es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/MPY 509/19es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional